VEGFA and spondylo-ocular syndrome: There is a growing body of evidence from several cohort studies to suggest that the addition of bevacizumab, a monoclonal antibody directed against VEGF-A, to oxaliplatin based chemotherapy can reduce the incidence of SOS by approximately a third in patients [7].